Activist investor Ancora Alternatives has accumulated a significant position in Ashland Inc and is calling for the US specialty chemicals company to pursue a full sale, arguing that a transaction could unlock substantial shareholder value, according top a report by Reuters.
The report cites a presentation document reviewed by Reuters as revealing that the Cleveland-based hedge fund envisages a scenario in which a sale of Ashland Inc could increase the company’s share price by at least 30%. Ancora is also prepared to escalate its campaign into a proxy fight if there is no meaningful progress ahead of the next director nomination window in September.
The activist began building its stake following a share price decline in April, triggered by weaker-than-expected quarterly results. The company, whose customers include major consumer and pharmaceutical groups such as L’Oréal, Estée Lauder and Pfizer, has seen its valuation under pressure amid concerns over earnings momentum and execution.
Shares in Ashland rose more than 6% following news of Ancora’s campaign, reflecting investor attention on the potential for strategic action. The company currently has a market capitalisation of approximately $2.7 billion.
Ancora argues that Ashland continues to trade at a discount to the sum of its parts, with its business segments potentially worth more under a breakup or outright sale. The firm estimates that a transaction could lift the stock to at least $76 per share.
The hedge fund said a sale process would likely attract interest from both strategic buyers and financial sponsors, given the company’s portfolio of specialty chemical assets and established customer base.
A key shareholder in Ashland is Standard Investments, the investment arm of industrial group Standard Industries, which holds close to a 10% stake and is the company’s largest investor. Market speculation has suggested it could be a potential participant in any future transaction, although it has not commented publicly.
Ancora has indicated that its public campaign is intended to encourage engagement with potential bidders while also increasing pressure on management and the board to evaluate strategic alternatives.
The firm is expected to formally present its case at the Wolfe Research Activist Conference, where it is set to outline its broader thesis for value creation through a sale process.
Ancora has built a reputation as an active shareholder across multiple sectors, having launched numerous campaigns in recent years at companies including Norfolk Southern and Kohl’s. Its approach has increasingly aligned with a wider industry trend of activists pushing for asset sales and corporate simplification as M&A activity accelerates.
While the firm has criticised Ashland’s recent performance under CEO Guillermo Novo, it has stopped short of explicitly calling for leadership changes, instead focusing its efforts on strategic action at the board level.
